Equities

Tristel PLC

Tristel PLC

Actions
Health CareHealth Care Providers
  • Price (GBX)435.00
  • Today's Change-12.50 / -2.79%
  • Shares traded32.31k
  • 1 Year change+32.82%
  • Beta0.3635
Data delayed at least 20 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tristel plc is a United Kingdom-based manufacturer of infection prevention products. The Company's core business is the sale to hospitals of its chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand, and for the sporicidal disinfection of environmental surfaces under the Cache brand. The Company’s segments include Hospital medical device decontamination, Hospital environmental surface disinfection and others. The Company manufactures and sells medical device decontamination products which are used primarily for infection control in hospitals. The Company also manufactures and sells hospital environmental surface disinfection products. The Company is also focused on pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare sectors. The Tristel brand offers airway management, cardiology, ear, nose and throat, ophthalmology, endoscopy, surfaces, ultrasound, urology, hand hygiene and women's health.

  • Revenue in GBP (TTM)39.49m
  • Net income in GBP6.04m
  • Incorporated2003
  • Employees213.00
  • Location
    Tristel PLCLynx Business Park,Fordham RoadSNAILWELL CB8 7NYUnited KingdomGBR
  • Phone+44 163 872 1500
  • Fax+44 163 872 1911
  • Websitehttps://tristel.com/hk-en/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stille AB21.84m1.97m119.76m106.0033.871.4339.445.485.315.3158.79126.110.514----2,782,019.004.647.035.218.1944.8243.939.049.856.543.36--21.9819.7016.78-2.485.3423.62--
Pulsion Medical Systems SE27.07m4.62m123.39m66.0026.725.2121.224.560.65490.65493.843.360.97111.773.88479,840.0016.5820.3721.2431.1763.6655.9617.0724.121.7715.740.001,227.726.103.02-8.06----0.00
ADDvise Group AB (publ)101.66m7.66m137.73m361.0023.744.078.771.350.55820.55827.393.260.52244.244.83--3.943.724.974.7765.4956.187.545.891.022.080.72460.940544.3038.6227.62--30.49--
Amplitude Surgical SA88.92m36.94m138.72m416.003.751.712.961.560.90020.90022.171.970.39550.56528.83244,244.1016.21-0.365819.44-0.426779.4178.3040.98-1.081.210.41630.5395--14.44-0.0271993.58--7.11--
Onward Medical NV0.00-30.82m141.46m96.00--4.21-----1.19-1.190.001.140.00----0.00-47.61---52.97-------------32.110.3163------4.49------
Prim SA185.04m10.83m146.33m894.0013.581.367.540.79080.740.7412.697.401.121.644.10--6.586.689.248.9048.7340.765.856.431.22--0.1681--9.7710.0051.02-2.14----
Bactiguard Holding AB16.52m-10.25m166.42m220.00--7.18--10.07-3.95-3.956.3710.080.30374.376.93---18.83-7.56-24.62-8.8127.4747.91-62.01-26.280.6445-8.670.3976---11.966.46-161.71--8.43--
Detection Technology Oyj-85.46bn-85.46bn175.98m478.00--2.83----------4.97----------9.34--11.96--47.44--8.223.13--0.08153.455.292.027.55-18.03-14.88-9.55
Tristel Plc39.49m6.04m206.60m213.0034.626.6224.155.230.12560.12560.82190.65670.9921.516.26185,394.4015.178.8617.1010.2482.5980.6315.2910.633.93411.730.1605109.9915.7010.14351.986.409.8818.05
Semperit Holding AG616.26m21.48m215.57m4.58k9.980.5934.040.34981.23-0.816235.1720.670.80984.688.24157,578.902.795.253.607.3222.4624.793.455.591.384.920.342686.85-7.54-3.87-34.59---7.21--
PharmaSGP Holding SE83.37m12.81m224.60m85.0017.547.1810.792.691.251.258.133.050.75921.159.691,234,848.0011.6714.6213.9821.2290.6189.9015.3719.172.159.030.6809--31.3410.0911.820.288614.67--
BICO Group AB167.75m-145.34m241.41m884.00------1.44-27.38-27.6631.82--------2,562,896.00--------47.29---86.69-----2.02----6.09---1,889.45------
Medistim ASA38.40m7.57m249.28m152.0032.788.5426.816.495.685.6828.7721.771.070.86465.983,462,921.0021.0122.9326.1428.5278.6778.2519.7220.642.61--0.042575.257.0010.06-8.9112.720.03314.87
Lumibird SA174.40m9.07m251.92m1.06k30.081.5611.571.440.43610.43618.318.430.55801.154.91203,864.102.903.843.594.8461.9061.595.206.901.523.620.38290.0017.5438.46-18.0845.5248.05--
Data as of Mar 28 2024. Currency figures normalised to Tristel PLC's reporting currency: UK Pound GBX

Institutional shareholders

63.46%Per cent of shares held by top holders
HolderShares% Held
Liontrust Investment Partners LLPas of 30 Jun 20235.59m11.77%
Charles Stanley & Co. Ltd. (Investment Management)as of 30 Jun 20234.74m9.99%
Rathbones Investment Management Ltd.as of 21 Sep 20233.35m7.06%
Schroder Investment Management Ltd.as of 01 Dec 20233.00m6.33%
Montanaro Asset Management Ltd.as of 30 Jun 20233.00m6.32%
Aviva Investors Global Services Ltd.as of 25 Sep 20232.94m6.18%
Investec Wealth & Investment Ltd.as of 30 Jun 20232.19m4.61%
Unicorn Asset Management Ltd.as of 30 Jun 20231.94m4.08%
BGF Investment Management Ltd.as of 27 Jul 20231.93m4.07%
Danske Bank A/S (Investment Management)as of 29 Sep 20231.45m3.06%
More ▼
Data from 31 Jul 2023 - 17 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.